INTRODUCTION
The coordinated movement of motile cilia on the lung epithelium is responsible for the upward transportation of lung mucus, wherein pathogens and harmful particles are captured. This process is called mucociliary clearance and is essential for keeping the lungs infection free. 1 Primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) are both rare, autosomal-inherited disorders associated with impaired mucociliary clearance. 2,3 Although both diseases have a different genetic and functional origin, they share common features such as chronic respiratory infections characterized by excessive neutrophil influx. Indeed, high neutrophil counts and elevated neutrophil chemoattractant levels, for example, C-X-C motif chemokine ligand 8/interleukin-8 (CXCL8/IL-8), are present in the lungs of PCD and CF patients, even during stable conditions. 4, 5 Despite the high neutrophil numbers and CXCL8/IL-8 levels, these patients suffer from persistent bacterial colonization and uncontrolled inflammation. 3 An overview of the most common clinical features in CF and PCD is listed in Table 1. CF is the most common lethal, inherited disease in Caucasians and is characterized by an early, uncontrollable and destructive activation of the innate immune system in the airways. 8 CF is caused by a defective CF transmembrane conductance regulator (CFTR), which is a chloride channel mainly expressed at the apical membrane of epithelial cells. In the airways, CFTR is an essential player in the regulation of the viscosity of the mucus and consequently in regulating mucociliary clearance. 9 PCD is less common than CF and is caused by structural and/or functional defects of the motile cilia. These defects lead to abnormal motility of the cilia, for example, of those lining the respiratory system. 2, 10, 11 Next to recurrent upper and lower airway infections, laterality defects and male infertility are also common symptoms in these patients (Table 1) . In up to 75% of the patients, symptoms start early in life. 2, 12 Diagnosis is often delayed, because the symptoms overlap with other, more common respiratory diseases. 2, 13 Today, mutations in more than 30 genes have been reported to be involved in PCD. 12 This review provides an overview on the knowledge of the role of chemoattractants and cytokines in the lung pathology of PCD and CF patients with a focus on the similarities and dissimilarities between these neutrophil-dominated lung diseases.
IMPAIRED MUCOCILIARY CLEARANCE
The apical surface of the airway epithelium is covered by a liquid layer, which serves as a first line of defense against invading pathogens. This liquid layer needs to be sufficiently fluid to allow ciliary movement so that the captured pathogens and particles in the mucus can be evacuated from the lungs. On the other hand, the mucus layer needs to be sufficiently viscous to shield the airway epithelium from toxic products. 1, 9 The chloride channel CFTR has a major role in defining the viscosity of the mucus layer. Improperly working CFTR leads to excessive dehydration of the mucus layer (for a more detailed explanation, refer to the paper of Livraghi and Randell 14 ) . Mucus dehydration impairs ciliary movement and leads to accumulation of pathogens in the airways. Consequently, CF patients suffer from uncontrollable airway infections. In PCD patients, inefficient mucociliary clearance is caused by defective motile cilia lining the airway epithelium. Similar to CF, bacteria accumulate in the lungs resulting in recurrent uncontrollable infections eventually leading to irreversible lung damage. 2, 15 In CF and adult PCD patients, Pseudomonas aeruginosa is the most common isolated bacterium in the lungs and its persistent colonization is related to gradually reducing lung function. 2, 16, 17 Next to P. aeruginosa, Staphylococcus aureus and Haemophilus influenzae are also common bacteria isolated from the lung sputum of both patient groups. 2,4 Stimulating mucociliary clearance and controlling bacterial infections are the most frequently applied treatments for these patients (see further).
NEUTROPHIL-DOMINATED LUNG PATHOLOGIES
The role of neutrophils in respiratory inflammation Airway epithelium signaling plays a significant role in the first steps to combat infection and to activate the innate immune system, which is essential for sensitive detection and rapid degradation of invading pathogens. 18 Toll-like receptors 4 (TLR4) and 5 (TLR5) recognize membrane proteins of P. aeruginosa, whereas TLR2 recognizes conserved microbial structures of Gram-positive bacteria (e.g., S. aureus). TLR2, -4 and -5 are expressed by airway epithelial cells and most immune cells, including neutrophils, and play a major role in triggering of the innate immune response. 19 Airway epithelial cells respond to inhaled bacteria by producing anti-microbial mediators, to directly target the bacteria, and cytokines and chemoattractants to activate and recruit neutrophils and other immune cells to the site of infection. 5, 18 Recruitment of blood neutrophils to the respiratory system is mediated by several chemoattractants, for example, the chemokine CXCL8/IL-8 and the lipid-mediator leukotriene B4 (LTB4). 8, 17 Neutrophils are the first immune cells to arrive at the site infection and their anti-bacterial response is essential during the first stages of the inflammatory process. Phagocytosis, neutrophil extracellular trap (NET) formation and the release of reactive oxygen species and proteases are potent mechanisms to kill pathogens. 20 However, the release of these toxic agents does not only target pathogens but also damages healthy lung tissue and therefore needs to be tightly regulated by a complex balance of anti-inflammatory and proinflammatory cytokines to avoid tissue damage. 17, 20, 21 Normally, inflammation is restrained and resolved through production of antiinflammatory cytokines, such as IL-10, which induce apoptosis of immune cells to terminate Inflammation. However, several aspects of the immune response have been shown to be abnormal in lungs of CF patients. 15 More specifically, in CF and PCD, elevated levels of several proinflammatory cytokines are detected in the lung sputum (vide infra). Consequently, high neutrophil influx is detected in the lungs of these patients.
Chemoattractants and neutrophils in chronic airway inflammation Airway inflammation plays a central role in the disease progression of CF and PCD and is dominated by abundantly infiltrated neutrophils. 3, 15, 22 Although present at large numbers in the infected lung, neutrophils fail to clear infections. Instead, these cells fuel a vicious cycle of structural damage to lung epithelium and promote bacterial colonization and further neutrophil influx and activation, which makes it difficult to control inflammation in these patients. 8 CFTR is required for hypochlorous acid production during the respiratory burst and is essential for intracellular bacterial killing in lysosomes. 23 Dysregulated CFTR is known to directly affect neutrophil activity. In CF patients, airway neutrophils display an aberrant behavior in their killing mechanisms and show reduced apoptosis. 23 Moreover, lower TLR2 and higher TLR4 expression was measured on blood CF neutrophils and airway CF neutrophils, respectively. 24 However, others reported similar TLR4 expression, but higher TLR5 expression on airway CF neutrophils compared to healthy individuals. 25 Under stable conditions, blood neutrophils of CF patients displayed an increased migratory response to CXCL8/IL-8. 26 Upon infection, however, CF neutrophils showed reduced in vitro chemotactic responses to LTB4 and suboptimal concentrations of CXCL8/IL-8, but not to N-formylmethionyl-leucyl-phenylalanine (fMLF) and complement component 5a (C5a). 27, 28 The reduced response to CXCL8/IL-8 is correlated with receptor desensitization because of high systemic CXCL8/IL-8 levels. 27 Moreover, Corvol et al. 29 demonstrated that both unstimulated and LPS-induced blood and airway neutrophils from CF patients produced more CXCL8/IL-8 and less of the antiinflammatory IL-1-receptor antagonist (IL-1ra) compared to healthy individuals and patients with PCD. 29 Furthermore, airway neutrophils produced spontaneously more CXCL8/IL-8 than blood neutrophils in CF patients, indicating that inflammatory conditions in CF lungs influence the responsiveness of neutrophils. 29 Unstimulated blood neutrophils from CF patients compared to healthy subjects produced significantly higher CXCL8/IL-8 levels before and after antibiotic treatment and showed increased expression of phagocytosis and adhesion receptors. 30, 31 Neutrophils are able to secrete proinflammatory cytokines and chemokines themselves, although in lower quantities than for example macrophages. 32 Still, because present in high numbers in CF and PCD lungs, neutrophils could be relevant contributors to CXCL8/IL-8, IL-1β and other cytokine production in respiratory diseases. Overall, these data suggest that CF neutrophils display an active state, even in stable conditions. Consequently, neutrophil density in CF lung correlates with reduced forced expiratory volume in 1 s (FEV 1 ) and thus disease severity. 33, 34 For PCD patients, some studies reported no significant abnormality in neutrophil migration. 35, 36 However, reduced in vitro migration of peripheral blood PCD neutrophils to fMLF, LTB4 and C5a has also been reported. [37] [38] [39] Recently, our group demonstrated that peripheral neutrophils from pediatric patients with PCD migrated less to the chemokines CXCL5/ENA-78 and CXCL8/IL-8, whereas their migratory response to LTB4 and C5a was normal compared to healthy individuals. 40 These results could be a first indication of abnormal neutrophil activity in patients with PCD.
The role of airway epithelial cells in CF and PCD Airway epithelial cells create several barriers in the defense against pathogens to prevent invasion of the respiratory system. The secretion of cell-associated and secreted mucins forms a liquid barrier, that is, mucus, to catch harmful pathogens and particles. 18 Furthermore, airway epithelial cells release antimicrobial products and several proinflammatory chemokines, such as CXCL5/ENA-78, CXCL8/IL-8, C-C motif chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) and CCL5/RANTES (regulated on activation, normal T-cell expressed and secreted), to attract immune cells. 18, 41, 42 Several studies showed already that P. aeruginosa stimulates the transcription and excessive production of several cytokines in airway epithelial cells. 5, 43, 44 In vitro, it has been established that airway epithelial cells carrying mutant CFTR produced more CXCL8/IL-8, IL-6 and granulocyte-macrophage colonystimulating factor (GM-CSF) compared to normal epithelial cells (Figure 1 ). 43 As mentioned above, CXCL8/IL-8 regulates the chemotactic migration of neutrophils to the site of infection, while GM-CSF delays neutrophil apoptosis. 45 Generally, it is known that absence or deficiency of CFTR in epithelial cells is related to reduced production of the antiinflammatory mediators IL-10 and nitric oxide (NO). IL-10 and NO inhibit nuclear factor-κB (NF-κB), a nuclear transcription factor that activates gene expression of proinflammatory cytokines by airway epithelial cells and macrophages. 15, 43 Therefore, even without exogenous stimulation, epithelial cells produce high levels of CXCL8/IL-8 and other proinflammatory cytokines in CF patients. 46 Conflicting results are reported concerning TLR expression on CF airway epithelial cells. A few studies detected lower TLR2 and TLR4 expression on CF airway epithelial cells, which could be related to the altered innate and adaptive immune responses in CF, [47] [48] [49] whereas others found no differences in TLR expression on CF airway epithelial cells. 50, 51 Inducible NO synthase (NOS2) is constitutively expressed by airway epithelial cells. NO plays a role in host defense, regulating cytokine production and ciliary motility in the respiratory system. 52, 53 In PCD and CF patients, lower NO levels are detected in the exhaled breath condensate (EBC). 54, 55 Steagall et al. 56 demonstrated that CFTR activity regulates NOS2 mRNA levels and leads to lower NOS2 activity in patients with CF. Although nasal NO levels are lower in patients with PCD compared to healthy individuals and CF patients, no clearcut explanation has been found to explain this additional reduction for PCD compared to CF. 53 Today, measuring nasal NO levels is used as a diagnostic parameter in the two pathologies. 2 The role of mononuclear leukocytes in CF and PCD Although neutrophils are the major contributors to airway damage in CF, other immune cells are studied as well. Recently, the role of mononuclear phagocytes, that is, monocytes and macrophages, has been elucidated in the pathogenesis of CFrelated lung inflammation. Defective CFTR affects phagocytosis, adhesion and chemotactic migration of monocytes. 57, 58 Consequently, monocytes accumulate in the lung parenchyma Figure 1 Cytokines and chemoattractants contributing to the neutrophilic airway inflammation in CF and PCD. The figure shows the links between inflammatory mediators and (immune) cells in the airways and blood circulation of CF and PCD patients. The solid arrows indicate cytokine production, whereas the dotted arrows point to cell stimulation by cytokines or pathogens. In CF, airway epithelial cells carrying a defective CFTR channel produce CXCL8, GM-CSF and IL-6 even without adding external stimuli. Furthermore, the persistent P. aeruginosa colonization stimulates airway epithelial cells to secrete high levels of proinflammatory cytokines and chemoattractants, such as IL-1β, GM-CSF and CXCL8 (1). Neutrophils (PMN) in CF lungs also produce CXCL8 and IL-17 and consequently enhance their own activation and attraction to the lungs (2). P. aeruginosa colonies provoke alveolar macrophages (Mϕ) to produce high G-CSF, TNF-α, IL-1β and CXCL8 levels, increasing neutrophil activity (3). Monocytes with malfunctioning CFTR channels transmigrate less efficiently through the airway epithelium into the airway lumen and accumulate in the airway parenchyma. These monocytes, exposed to proinflammatory cytokines and chemoattractants produced by the epithelium or diffused from the airway lumen, secrete high levels of proinflammatory mediators, for example, CXCL8, CCL2, IL-6 and TNF-α, that activate peripheral blood neutrophils (4). IL-6 promotes Th17 cell (Th17) differentiation in the lungs. Th17 cells in turn produce high IL-17 levels, which indirectly stimulate neutrophil migration and activation (5) . High CXCL8, CCL2 and TNF-α levels are measured in the circulation of patients with CF, probably originating from the lungs (6). In PCD, the impact of chronic P. aeruginosa colonization on airway epithelial cells and on neutrophil activation and migration has not been studied yet (1). Similarly, CXCL8 production by neutrophils or macrophages in PCD lungs and its role in neutrophil activation is not known. The high CXCL8 levels in sputum of patients with PCD might contribute to the excessive neutrophil infiltration into PCD lungs (2). The role of alveolar macrophages in the airway lumen, together with the related cytokines and chemoattractants is not identified yet (3). So far, the function of monocytes and Th17 cells in PCD lungs has not been investigated and CXCL8, TNF-α and IL-1β levels are not yet determined in the circulation of patients with PCD (4-6). CCL2, C-C motif chemokine ligand 2; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CXCL8, C-X-C motif chemokine ligand 8; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; Mϕ, macrophage; PCD, primary ciliary dyskinesia; PMN, polymorphonuclear cells; Th17, T-helper type 17; TNF-α, tumor necrosis factor-α.
( Figure 1 ). Since monocytes are known to be a good cellular source of chemokines 59 and cytokines, 60, 61 these entrapped monocytes could be important producers of cytokines contributing to neutrophil migration and activation in the lungs, for example, CXCL8/IL-8, CCL2/MCP-1 and tumor necrosis factor-α (TNF-α). 57, 62, 63 Finally, circulating peripheral blood mononuclear cells from children with CF expressed similar TLR2, but higher TLR4 levels compared to healthy individuals. 64 Macrophage counts were significantly elevated in bronchoalveolar lavage fluid (BALF) of CF patients compared to other non-CF respiratory diseases. 65 In the latter study, a correlation between the number of macrophages and CC chemokine levels (CCL2/MCP-1, CCL3/MIP-1α, CCL4/ MIP-1β and CCL20/MIP-3α) in the BALF of pediatric CF patients was found, indicating that airway macrophages are probably an important source of these chemokines. Similar to monocytes, airway macrophages are a major source of several cytokines, such as IL-1α, IL-6, granulocyte colony-stimulating factor (G-CSF) and CXCL8/IL-8 ( Figure 1 ). 3, 16 Our group studied the cytokine and chemokine production by peripheral blood monocytes from pediatric patients with PCD. Upon stimulation with bacterial products (i.e., lipopolysaccharide and peptidoglycan), monocytes from PCD patients produced significantly more IL-1β and CXCL8/IL-8 compared to healthy individuals (unpublished data). Next to the study of Walter et al., 36 wherein normal chemotactic migration of monocytes from PCD patients is described, no other studies have investigated the role of monocytes in the pathogenesis of PCD patients.
Other mononuclear immune cells, such as lymphocytes and dendritic cells, are also detected in the sputum of CF. CFTR is expressed in these immune cells as well, however, its exact role in regulating activity of these immune cells is not known yet. 15, 65 Neither has their role in the pathogenesis of PCD been extensively studied. Moser et al. 66 investigated IL-4 and interferon-γ (IFN-γ) production by peripheral blood mononuclear cells from CF patients with and without P. aeruginosa infection. Mononuclear cells from patients with infection produced less IFN-γ and more IL-4 than cells from patients without infection. Moreover, in this study a correlation was found between IFN-γ levels and disease status. 66 
CYTOKINE/CHEMOATTRACTANT PROFILES OF CF AND PCD SPUTUM
Cytokines are indispensable players in regulating the innate and adaptive immune system during infection. 67 Next to recruiting immune cells to the site of infection and modulating their activity, cytokines also terminate cell activity to avoid an exacerbated immune response in order to protect the host. 21 The cytokine/chemoattractant profile of the sputum of CF patients has been investigated thoroughly. Next to CXCL8/IL-8, GM-CSF and IL-6, higher levels of CCL2/MCP-1, CCL3/ MIP-1α, CCL4/MIP-1β, CCL20/MIP-3α, TNF-α, IL-1β, IL-17, IL-23, G-CSF and LTB4 are found in BALF and/or sputum of CF patients, even during stable conditions. IL-10 and CCL5/ RANTES levels were found to be lower in the sputum of CF patients compared to individuals with other respiratory infections. 15, 41, 43, 45, 65, [68] [69] [70] [71] [72] The lower CCL5/RANTES levels correlated with defective CFTR, which was demonstrated to regulate CCL5/RANTES mRNA transcription. 41 Although CCL2/MCP-1 is a potent activator of monocytes rather than neutrophils, it synergizes with CXCL8/IL-8 to enhance neutrophil chemotaxis (Figure 1) . 73 In acute respiratory distress syndrome, chemokine synergy is reported to be involved in neutrophil migration to the lungs. 74, 75 The role of T-helper type 17 (Th17) cells in CF lung inflammation has received great interest over the past years. 76 IL-6 and IL-23, two cytokines elevated in BALF of CF patients, stimulate Th17 cell differentiation and these cells secrete high levels of IL-17. This cytokine is essential for the clearance of bacteria and the resolution of inflammation. 77 On the other hand, during chronic inflammation, IL-17 can enhance lung pathogenesis by promoting the recruitment and activation of neutrophils (Figure 1 ). 77 Moreover, IL-17 stimulates the production of proinflammatory cytokines (e.g., TNF-α, IL-1β and CXCL8/ IL-8) and seems to be involved in airway remodeling by promoting production of the profibrotic cytokines IL-6 and IL-11. Thus, IL-17 is a major contributor of the vicious cycle of airway inflammation in CF. In the lungs of CF patients, airway macrophages are an important source of the elevated IL-1β, TNF-α, CXCL8/IL-8 and CC chemokines, probably due to continuous cell activation by the persistent P. aeruginosa colonization (Figure 1) . 15, 65 A study of Osika et al. 69 revealed that in pediatric patients with CF, no correlation was found between cytokine levels in the lung sputum and FEV 1 or presence of bacterial colonization. Moreover, no significant difference in TNF-α, IL-6, CXCL8/IL-8 and IL-10 levels was detected in the lungs of stable patients, patients with exacerbation before treatment and patients with exacerbation after treatment. Only IL-1β concentrations were significantly higher in patients with exacerbation before treatment compared to stable patients and patients with exacerbation after treatment. 69 Other research groups also reported similar inflammatory mediator profiles in stable and exacerbating CF patients. [78] [79] [80] This implicates that even during stable conditions, high proinflammatory cytokine and low anti-inflammatory cytokine levels endure in the lungs of CF patients and are likely contributing to the chronic airway inflammation observed in these patients. In CF patients, systemically elevated CXCL8/IL-8, CCL2/MCP-1 and TNF-α levels were measured, probably caused by leakage from lung tissue into the blood circulation. 72, 81 A few studies measured higher CXCL8/IL-8 levels in the sputum of patients with PCD compared to patients with CF, although the clinical outcome for PCD patients is more favorable. 4, 82 Sputum characteristics during stable conditions versus exacerbations in patients with CF and PCD were compared to explore why the outcome in CF patients is worse. 4 During exacerbation, neutrophil counts were higher in PCD patients, whereas in CF patients, higher total bacterial density was detected. After antibiotic treatment, bacterial density remained similar in PCD patients, but lowered in CF patients. In both patient groups, CXCL8/IL-8 concentration in sputum did not significantly change after treatment. 4 Equal neutrophil elastase (NE) activity was measured in sputum from PCD and CF patients during exacerbation and stable conditions. NE is a serine protease involved in intracellular and extracellular destruction of pathogens, but also destroys host components (e.g., membrane receptors and channels) during excessive neutrophil activation. 83 Antibiotic treatment decreased elastase activity in patients with PCD, but not in CF patients. 4 Overall, these results suggest that patients with PCD show a better response to antibiotic treatment compared to patients with CF. Moreover, NE stimulates CXCL8/IL-8 production by airway epithelial cells and thus contributes to the high CXCL8/IL-8 levels in CF lungs. 15, 17 NE activity in sputum is believed to be the best predictor of lung function decline in CF and could explain the much faster decline in CF patients compared to PCD patients. 71, 84 Some research groups reported a significant inverted correlation between FEV 1 and CXCL8/IL-8 concentrations, 34, 85 whereas others found no correlation between FEV 1 and CXCL8/IL-8 concentrations in sputum. 69, 79 This difference in results is probably due to different selection criteria for patients with CF. Indeed, in some studies the patients were divided according to their disease severity, whereas in other studies all patients were considered as one group. Furthermore, high ROS concentrations were found in CF sputum, which is, next to high CXCL8/ IL-8 and NE levels, also indicative for enhanced neutrophil activity in the lungs of CF patients. 15, 71 As already mentioned, the sputum of PCD patients is far less studied. Elevated sputum levels of CXCL8/IL-8 were detected in PCD, 4,82 which were even higher than in CF (Figure 1 ). 82 Cytokines, other than CXCL8/IL-8, are not intensively studied in PCD compared to CF. Cultured nasal epithelial cells from patients with chronic rhinosinusitis, a common symptom in PCD, constitutively produced proinflammatory cytokines such as CXCL8/IL-8 and CCL2/MCP-1. 86 In the PCD mouse models, that is, nm1054 −/− (loss of PCD protein 1) and bgh −/− (loss of sperm flagellar protein 2) mice, elevated cytokine levels were detected in the respiratory system upon Streptococcus pneumoniae infection. 87 Bgh −/− mice showed elevated TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-17 and IL-10 levels in BALF, whereas in nm1054 −/− mice, only TNF-α, IL-2 and IL-6 were significantly elevated in BALF. High neutrophil influx was only observed in the airways of bgh −/− mice. These differences between PCD mouse models emphasize how heterogeneous the pathogenesis of airway inflammation in PCD is and how difficult it is to find a general therapy for these patients. Zihlif et al. 88 measured LTB4 and CXCL8/IL-8 levels in EBC of stable PCD patients and healthy individuals. CXCL8/IL-8 was not detectable in EBC and LTB4 levels were similar between PCD patients and healthy individuals, indicating that, in contrast to CF patients, LTB4 levels are normal in PCD patients.
Thus, in contrast to PCD, proinflammatory cytokine levels are already used as sensitive markers for pulmonary bacterial colonization and inflammation in CF patients. 89 In addition to a measure to evaluate disease severity, pulmonary biomarkers Antibiotic treatment directed to sputum-isolated pathogens (inhaled or oral) Prevention of P. aeruginosa infection:
• Antibiotic therapy early after infection (inhaled or oral) Suppression of chronic P. aeruginosa infection:
• Chronic use of inhaled antibiotics (e.g., tobramycin, aztreonam lysine)
Airway inflammation
Anti-inflammatory agents (e.g., ibuprofen, azithromycin) Anti-inflammatory agents (e.g., ibuprofen, azithromycin) are also more frequently used to predict treatment responses of individual CF patients. 15 
ANTI-INFLAMMATORY DRUGS FOR LUNG PATHOLOGIES
Today, the treatments applied for CF and PCD mainly aim to control bacterial infections and to maintain lung function by the administration of antibiotics and the stimulation of mucociliary clearance, respectively. 90, 91 However, no treatment has been developed yet to completely remedy bacterial infections in the respiratory system of these patients. Biofilm formation of P. aerugonisa in the lungs of CF patients protects the bacteria against antibiotics, which makes it more difficult to clear the respiratory system from infection. 92, 93 Moreover, because of differences in disease severity, not all patients respond equally well to these treatments. 6, 94 Suppressing airway inflammation is the most important aim when treating these respiratory diseases. 15 Since PCD and CF are neutrophildominated lung diseases, attenuating neutrophil activity seems to be a possible option. Several clinical studies tried to subdue the excessive inflammation by targeting neutrophil influx and/ or release of neutrophil products. 16 A short overview of the most frequently applied medical treatments in PCD and CF patients and their effects on cytokine levels and neutrophil activity in lung sputum are discussed below and summarized in Table 2 . Owing to lack of clinical trials, treatment of PCD patients is based on data of patients with CF and other respiratory diseases. 96 
Antibiotic treatment
In a study by Cunningham et al., 78 intravenous antibiotic treatment led to mild improvement in lung function, but had no significant effect on the proinflammatory cytokine levels in the lung sputum of CF patients. Moss et al. 97 and Ordonez et al., 98 however, did measure significantly lower CXCL8/IL-8 levels and neutrophil counts after intravenous antibiotic application. Moreover, other research groups measured significantly lower TNF-α and IL-17 levels in treated CF patients compared to untreated patients. 68, 99 The inhalation of tobramycin by CF patients was investigated as well, and a decline in CXCL8/IL-8, IL-6 and TNF-α levels and lower P. aeruginosa colonization was reported in response to this therapy. However, neutrophil counts remained high. 89 Oral application of the macrolide clarithromycin, acknowledged to reduce neutrophil activity, did not affect sputum proinflammatory cytokine levels and neutrophil counts in CF patients. 98 Lung function improved modestly and the number of exacerbations declined in CF patients treated with azithromycin, which is believed to have both antibiotic and anti-inflammatory properties. However, no differences in P. aeruginosa density and CXCL8/IL-8 levels were detected in the sputum of the treated versus non-treated patients. 16, [99] [100] [101] The applied antibiotic treatment for PCD is based on the type of bacteria isolated from the lung sputum. 12 Generally, bacterial load is decreased significantly after intravenous and inhaled antibiotic treatment and lower doses than in CF patients are needed. 94 The optimal duration of the antibiotic treatment in PCD patients is not defined yet. Although there are no clinical trials to provide conclusive evidence, intravenous antibiotic treatment needs to be considered when the patient's conditions do not improve with oral antibiotics. 96 Based on the successful results in CF and other respiratory diseases, the easy intake, the targeting of a wide range of bacteria and the mild side effects, a clinical trial using azithromycin to maintain lung function in PCD patients has recently been started. 90 A case study by Itoh et al. 102 described an improvement in lung function in a 30-year old PCD patient after treatment with azithromycin.
Recombinant human deoxyribonuclease Sputum of CF patients contains high DNA concentrations due to enhanced NET release by neutrophils. NETs are expulsed DNA strands decorated with histones and several proteolytic enzymes, for example, NE, to capture and degrade pathogens. 103 Next to pathogens, cytokines such as TNF-α, IL-1β and CXCL8/IL-8 stimulate NET release by neutrophils. 103 These NETs contribute to airway epithelium damage and increase mucus viscosity even further in CF patients. Recombinant human deoxyribonuclease (rhDNase) degrades DNA and is currently used as a treatment for patients with CF. Several studies showed that rhDNase treatment reduces sputum viscosity, improves lung function and lowers the number of pulmonary exacerbations in CF patients with moderate lung disease. 104 However, following the release of proteolytic enzymes from the DNA strands, the airway epithelium is exposed to high proteolytic activity. 5 Although lung function seemed to improve during rhDNase treatment, generally only a minor reduction in proteolytic (NE) activity and CXCL8/IL-8 concentrations was observed in rhDNasetreated CF patients. 17 During a treatment period of 1 to 3 months, no changes in neutrophil counts or inflammatory cytokine levels were measured in the respiratory system. 105, 106 However, treatment of CF patients with rhDNase for 3 years prevented an increase in several inflammatory mediators in the lungs. 107 A clinical trial to study the use of rhDNase treatment in PCD patients has not been elaborated yet. However, a few case studies reported some promising results and described beneficial effects of both short-and long-term use of rhDNase on lung function in PCD patients. [108] [109] [110] Because DNA levels in sputum of PCD patients are not as high as in CF and are even not detectable in some PCD patients, the use of rhDNase treatment in PCD patients is still a matter of debate. 96, 111 Classical anti-inflammatory drugs Caution must be taken when administering anti-inflammatory therapies, especially during severe bacterial infections. Reducing the inflammatory capacity of neutrophils and/or other immune cells could increase disease severity. 3 None of the above mentioned treatments (see 'Antibiotic treatment' and 'rhDNase') is capable to eliminate the chronic airway inflammation in CF patients and therefore, several research groups tried to reduce the inflammation by decreasing neutrophil activity. In other lung diseases, several therapeutics targeting neutrophil migration and/or activation are successful in diminishing inflammation. 112 Corticosteroids were the first anti-inflammatory medication applied in CF patients. 100 Although oral intake of corticosteroids had many beneficial effects on lung inflammation, several systemic adverse effects were reported in clinical trials. Inhaled corticosteroids, however, had less adverse effects but did not lower the lung inflammation in CF. Today, short-term inhaled corticosteroids are advised in young patients without signs of development of asthma or other allergies in the lungs. 100 Ibuprofen has a broad range of anti-inflammatory effects. 16 Treating CF patients with a high dose of ibuprofen for 1 month lowers neutrophil migration into the airways. 113 How ibuprofen lowers neutrophil migration has not been elucidated yet, but may be explained by reduced upregulation of the adhesion molecule CD11b and actin polymerization upon CXCL8/IL-8 and C5a stimulation. 114 Lands et al. 115 performed a 2-year multicenter trial and detected improvements in lung function compared to the placebo group. Several clinical centers recommend ibuprofen for daily use in CF patients, 16, 76 however, it is not generally applied in all CF patients because of side effects and limited testing in multicenter trials. 16 In conclusion, anti-inflammatory therapy in CF is not successful yet. The clinical benefits of anti-inflammatory drugs cannot overcome the major side effects observed in treated CF patients. 15 Although, anti-inflammatory therapies do not improve lung function, they may slow down lung function decline over time. 15 So far, only a few clinical trials have been performed using anti-inflammatory drugs in PCD patients. 96 As mentioned before, a clinical trial was started to investigate the effect of the antibiotic azithromycin, which also has anti-inflammatory properties. 90 Today, however, anti-inflammatory strategies, such as alternate-day prednisolone or inhaled corticosteroids, are not routinely recommended in PCD. 96 
Experimental therapies
To reduce CF pathology, several research groups aim at crucial molecules contributing to the excessive lung inflammation. However, not all details of CF lung pathology are known yet and reducing crucial components of the (innate) immune response can worsen disease severity. A few strategies targeting inflammatory mediators are listed in Table 3 .
Bypassing the low IL-10 concentrations in the airways of CF patients by IL-10 administration could be beneficial to dampen inflammation. P. aeruginosa infected IL-10 − / − mice showed a reduced inflammatory response when treated with IL-10. 100, 116 More study is needed to confirm these results.
Targeting important regulators and chemoattractants that mediate neutrophil migration and/or activity, that is, CXCL8/ IL-8, intercellular adhesion molecule-1 (ICAM-1), IL-17 or LTB4, is a possibility to limit neutrophil influx. 16, 17, 68, 76, 77 CXCL8/IL-8 is targeted by small-molecule antagonists blocking its receptor, namely CXCR2. 119, 123, 124 Administration of a CXCR2 antagonist to CF patients led to lower neutrophil levels in the lungs. 119 However, high CXCL8/IL-8 levels in lung sputum and serum were still measured in these patients after treatment and the long-term effects of this antagonist have not been elucidated yet. Since application of a CXCR2 antagonist in chronic obstructive pulmonary disease patients improved lung function, clinical trials in CF patients are still justified. 123 Jundi and Greene 120 described alternative strategies targeting the high CXCL8/IL-8 levels in the lungs of CF patients. Additional in vitro studies are available wherein several approaches are investigated to inhibit CXCL8/IL-8 expression or production (e.g., NF-κB inhibitors) and activity (e.g., interfering with its binding to glycosaminoglycans). 120 If a suitable strategy is found, it could possibly be applicable in patients with PCD as well.
Neutralizing IL-17A activity has been studied in CFTRdeficient mouse models. Although IL-17 has a protective role during infection, impairing its function by using monoclonal antibodies led to a significant reduction in numbers of infiltrating neutrophils, less prominent proinflammatory cytokine production as well as reduction in tissue damage. 117, 118 Furthermore, anti-IL-17 monoclonal antibodies are shown to improve pathology in autoimmune diseases. 125 These results are promising for possible future application in CF.
A clinical trial investigating an LTB4 receptor antagonist to reduce airway inflammation in CF patients was interrupted because of reduced lung function in treated CF patients compared to patients receiving placebo. 121 These data emphasize that targeting the immune system to prevent inflammation is not straight forward and needs to be performed with great caution. Instead of modifying neutrophil migration, a few clinical trials in CF patients are currently running wherein neutrophil-derived proteases are targeted, for example, with inhaled alpha 1-antitrypsin and alpha1-proteinase inhibitor. 76 Using plant derivatives to attenuate inflammation has gained interest the last few years. The flavonoid phloridzin tetraproprionate is known to have anti-inflammatory effects by modulating NF-κB activity. 122 Recently, the effect of phloridzin has been studied in vitro in bronchial epithelial cells carrying a deficient CFTR gene. CCL5/RANTES, IL-10, IL-12, IL-17, GM-CSF and G-CSF mRNA expression levels as well as IL-6 and CXCL8/IL-8 production levels were reduced in the CFTRdeficient bronchial epithelial cells after TNF-α stimulation compared to normal bronchial epithelial cells. 122 Furthermore, the administration of lactoferrin, a defense glycoprotein molecule secreted by neutrophils, in mice challenged with acute or chronic P. aeruginosa resulted in a significant decrease in neutrophil recruitment and proinflammatory cytokine levels in the lungs. 126 Using such endogenous mediators to diminish airway inflammation could thus be a possible novel anti-inflammatory strategy for the future.
Finding a specific array of biomarkers of inflammation could play a major role for the development of anti-inflammatory therapies for PCD and CF lung pathologies. 15 These biomarkers are necessary to assess the inflammation level in the airways and will allow a quantitative determination of the efficiency of the drug under investigation.
CONCLUDING REMARKS
Lung pathogenesis in CF patients has been investigated thoroughly, whereas only a few studies examined the pathology in PCD patients. Can the knowledge of CF lung pathology be extrapolated to PCD? In CF, the uncontrollable airway inflammation is not a secondary response to infection. Lack of CFTR has several effects on cytokine production by airway epithelial cells and immune cell activity, such as phagocytosis and reactive oxygen species production. So far, it is not known if airway inflammation in PCD patients is a secondary effect or if the genetic defects directly influence immune system activity. Both lung pathologies show heterogeneity in symptoms and severity of disease. The correct treatment for both diseases is probably patient specific. Extrapolating data from CF to PCD could be useful, but must be done with great caution. Overall, CF patients require a more aggressive therapy than PCD patients. More research and clinical trials are needed to validate current therapies applied in PCD patients. Today, however, management of PCD differs between countries and clinical centers and PCD patients would benefit from standardized diagnosis and treatment protocols. 127 
